Inhibikase Therapeutics - IKT Aggregate Business Value
The price visualization on GURU.Markets for Inhibikase Therapeutics (IKT), which assists in the basic asset valuation, shows an Enterprise Value of 57.26. Inhibikase Therapeutics develops treatments for brain pathologies, leveraging university partnerships to accelerate trials for Parkinson's disease drugs. The environmental footprint is minimal due to the specific nature of laboratory research. The project's success is driven by outstanding specialists who have access to significant capital and creative independence.
Summary analytical data breakdowns for Inhibikase Therapeutics (IKT)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital Inhibikase Therapeutics|IKT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital inhibikase.com|IKT - Company Debts|Debts to Book Value Inhibikase Therapeutics|IKT - Company Long-Term Debts|Short-Term Debt Volume Inhibikase Therapeutics|Immediate Liquidity Ratio inhibikase.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Inhibikase Therapeutics
The development of long-term treatments for neurodegenerative diseases with patent protection creates high fundamental asset value for Inhibikase Therapeutics (IKT). The enterprise value trajectory reflects this value by summing market capitalization and debt minus cash, allowing investors to assess the real cost of a full business acquisition while accounting for its financial leverage and liquidity.
Who Inhibikase Therapeutics competes with
Enterprise Value Biogen Inc BIIB|NBIX: Real Price to Acquire Entire Company|Regencell Corp - Aggregate Business Value|Axsome Therapeutics (AXSM) - Total Company Value|Business Value ACAD|XENE (Xenon) - Enterprise Value|Total Enterprise Value Viking Therapeutics Inc VKTX|Real Price to Acquire Entire Company SUPN (Supernus Pharma)|Enterprise Value Catalyst Corp (CPRX)|Total Company Value Denali Therapeutics DNLI|Value Adjusted for Debt and Cash HRMY|BHVN - Total Company Value|Total Enterprise Value Amylyx Pharmaceuticals Inc|TRVI: Enterprise Value|PRAX - Company Buyout Price|Total Company Value Anavex Life Sciences|Business Value CBLL (ceribell.com)|Enterprise Value PRTA|ALEC (alector.com) - Value Adjusted for Debt and Cash|Enterprise Value ANNX (Annexon Inc.)|Company Buyout Price Omeros Corp (OMER)|Neurogene Inc. - Enterprise Value|ACIU: Total Company Value|VYGR: Enterprise Value|NMRA - Company Buyout Price|Total Company Value Scilex Holding Co.|Enterprise Value Tevogen Bio Inc.|Enterprise Value ACOG|Enterprise Value Cognition Therapeutics Inc. (CGTX)|Total Company Value Cassava Sciences SAVA|Company Buyout Price Assertio Holdings (ASRT)|Coya - Enterprise Value|Total Enterprise Value Vistagen Therapeutics|OVID (ovidrx.com) - Real Price to Acquire Entire Company|acumenpharm.com - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company CRVO|ATHE (Alterity Therapeutics Ltd) - Aggregate Business Value|Enterprise Value CLNN|PEPG (pepgen.com) - Value Adjusted for Debt and Cash|Enterprise Value JUNS (Jupiter Neurosciences)|relmada.com (RLMD) - Total Enterprise Value|ANVS - Total Company Value|Value Adjusted for Debt and Cash GRCE (Grace Therapeutics, Inc.)|AIFF: Enterprise Value|Klotho Neurosciences (KLTO) - Enterprise Value|Total Company Value NeuroSense Therapeutics Ltd|revivapharma.com - Full Business Value|Enterprise Value MTVA|NRXS - Total Enterprise Value|Helius Medical Technologies - Real Price to Acquire Entire Company|Enterprise Value Passage Bio Inc. PASG|NEUP: Real Price to Acquire Entire Company|minervaneurosciences.com - Aggregate Business Value|ATHA: Enterprise Value|ADXN - Company Buyout Price|ALZN (Alzamend Neuro Inc.) - Enterprise Value|Real Price to Acquire Entire Company Cyclerion (CYCN)|Total Company Value Protagenic Therapeutics (PTIX)|Company Buyout Price pasitheaclinics.com|Enterprise Value CRGT (Cortigent)|Company Buyout Price Avenue Therapeutics Inc. (ATXI)|BCLI - Total Company Value|CARA - Enterprise Value|CHRO (Chromocell Therapeutics) - Real Price to Acquire Entire Company|ELYM: Aggregate Business Value|Total Company Value Intra-Cellular Therapies Inc.|Business Value LBPH (Longboard Pharmaceuticals Inc)|Enterprise Value MRNS|NKGN - Total Enterprise Value|NeuroBo Pharmaceuticals - Real Price to Acquire Entire Company|Enterprise Value sagerx.com SAGE|SNPX - Total Company Value|Value Adjusted for Debt and Cash TRVN (Trevena Inc.)|vigilneuro.com (VIGL) - Total Company Value|Total Enterprise Value anewmeds.com (WENA)|CERE (Cerevel Therapeutics) - Enterprise Value